Proteins that are engineered in the laboratory for pharmaceutical use are known as therapeutic proteins. The majority of biopharmaceuticals marketed to date are recombinant therapeutic protein drugs. But how much potential does this market have? Will the shortfall in manufacturing capacity dampen its growth? Will the high cost of these drugs ever be reduced? And how imminent is the threat from biogeneric competition? These and many other questions will be answered in this comprehensive 230-page report on the market for therapeutic proteins.

In 2003, the market for therapeutic proteins grew by almost 19% to $37 billion, and is predicted to achieve sales of over $90 billion by 2010. Future growth however depends largely on the industry overcoming a number of hurdles, including drug delivery challenges and cost issues.

Today therapeutic proteins are used to relieve patients suffering from many conditions, including:

Various cancers (Monoclonal antibodies, Interferons)
Heart attacks, strokes, cystic fibrosis, Gaucher's disease (Enzymes, Blood factors)
Diabetes (Insulin)
Anaemia (Erythropoietin)
Haemophilia (Blood clotting factors)
The leading therapeutic protein treatments in 2003 were:
Johnson & Johnson's anaemia treatment Procrit
Amgen's anaemia treatment Epogen
Schering-Plough's hepatitis treatments Intron A and Peg-Intron
The leading classes of therapeutic proteins in 2003 were:
Erythropoietins
Monoclonal antibodies
Interferons
While the top companies on the market were:
Amgen
Johnson & Johnson
Roche

WHY YOU MUST BUY THIS REPORT?

With over 80 graphs and figures, plus almost 60 tables, this report represents a key tool for companies wishing to enter into or expand in the therapeutic protein market. The reader will be left with a clear idea of:

The challenges faced by the therapeutic protein market, and how these are being overcome
The current and future market leaders in terms of brand, class, category and company, covering the period 2003-2010

Therapeutic targets currently being developed in the field and who is responsible for this development

The competition that companies will face during the forecast period from current and pipeline products